New developments in castrate‐resistant prostate cancer
New developments in castrate‐resistant prostate cancer
复制标题
DOI：
10.1111/j.1464-410x.2012.11217.x
复制
发表时间：
2012-06
影响因子：
4.5
通讯作者：
N. Shore;M. Mason;T. D. Reijke
中科院分区：
文献类型：
--
作者：
N. Shore;M. Mason;T. D. Reijke
去势抵抗前列腺癌(CRPC)是在去势的雄激素水平存在的情况下疾病的进展，并且对进一步的激素操作仍然敏感。多年来，CRPC的治疗仅限于使用多西紫杉醇治疗转移性疾病。然而，随着几家新代理商的批准，这种情况最近发生了变化。SiPuleucel-T是一种免疫治疗性疫苗，目前在美国可用于非转移性CRPC患者，阿比特龙(一种雄激素生物合成的口服酶抑制剂)以及卡巴紫杉醇(一种细胞毒性化疗药物)已被批准用于治疗转移性CRPC。此外，地诺舒单抗是一种皮下抗体，现在除了静脉注射双膦酸唑来膦酸外，还可以用于治疗伴有骨转移的CRPC患者。
Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease. However, this has recently changed with the approval of several new agents. Sipuleucel‐T, an immunotherapeutic vaccine, is now available in the US for patients with non‐metastatic CRPC and abiraterone, an oral enzyme inhibitor of androgen biosynthesis, as well as cabazitaxel, a cytotoxic chemotherapeutic, have been approved for the treatment of metastatic CRPC. Also, denosumab, a subcutaneous antibody, is now an option for the treatment of patients with CRPC with bone metastases, in addition to zoledronic acid, an intravenous bisphosphonate.